How does a tumor acquire all those resistance promoting alterations in the first place? Kudos to Avantika Gupta Memorial Sloan Kettering Cancer Center for defining the role of #APOBEC3 mutagenesis in this process. #SABCS24

Honored to present our work on mechanism of mtTP53 in escaping CDK4/6i-induced geroconversion linked to the lack of long-term disease control. Grateful to Neil Vasan for highlighting our research in the Basic Science Year in Review! #SABCS24

🎥Avantika Gupta of Memorial Sloan Kettering Cancer Center discusses resistance to trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer. EGFR overexpression limits uptake, but adding cetuximab restores efficacy: ➡️ow.ly/Lt8Q50UAkJS⬅️ SABCS #SABCS24 #BreastCancer #BCSM #ImmunoOnc

🎥Avantika Gupta of Memorial Sloan Kettering Cancer Center discusses APOBEC3 signatures as biomarkers of poor outcomes in metastatic breast cancer. Targeting APOBEC-PIK3CA mutations may boost PI3K-alpha inhibitor sensitivity: ➡️ow.ly/TKE850UAkYO⬅️ SABCS #SABCS24 #BCSM #breastcancer

Sarat Chandarlapaty expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!

Thank you for your support! Excited to share the story with everyone soon!

A new study in Nature Genetics from MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: go.nature.com/45kkqfg